Get the Stockscreener App
2.47
0.00%
+0.00
After Hours:
2.47
MDxHealth SA ADR stock is currently priced at $2.47, with a 24-hour trading volume of 26,967.
It has seen a +0.00% increased in the last 24 hours and a -0.80% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $2.51 pivot point. If it approaches the $2.42 support level, significant changes may occur.
Previous Close:
$2.47
Open:
$2.46
24h Volume:
26,967
Market Cap:
$67.40M
Revenue:
$63.69M
Net Income/Loss:
$-44.82M
P/E Ratio:
-1.0292
EPS:
-2.4
Net Cash Flow:
$-30.56M
1W Performance:
+10.76%
1M Performance:
-0.80%
6M Performance:
+4.22%
1Y Performance:
-37.78%
1D Range:
$2.45
$2.5816
52W Range:
$2.15
$4.64
MDxHealth SA ADR Stock (MDXH) Company Profile
Name
MDxHealth SA ADR
Sector
Industry
Phone
32 4 257 70 21
Address
CAP Business Center, Rue d’Abhooz 31 Zone Industrielle des Hauts-Sarts, Herstal
MDxHealth SA ADR Stock (MDXH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-31-23 | Initiated | TD Cowen | Outperform |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
MDxHealth SA ADR Stock (MDXH) Latest News
Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering
GlobeNewswire Inc.
These Analysts Increase Their Forecasts On MDxHealth After Q4 Results
Benzinga
Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results
GlobeNewswire Inc.
Agiliti (AGTI) Q4 Earnings Beat Estimates
Zacks Investment Research
DermTech, Inc. (DMTK) Reports Q4 Loss, Misses Revenue Estimates
Zacks Investment Research
MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6
GlobeNewswire Inc.
MDxHealth SA ADR Stock (MDXH) Financials Data
MDxHealth SA ADR (MDXH) Revenue 2024
MDXH reported a revenue (TTM) of $63.69 million for the quarter ending September 30, 2023, a +111.05% rise year-over-year.
MDxHealth SA ADR (MDXH) Net Income 2024
MDXH net income (TTM) was -$44.82 million for the quarter ending September 30, 2023, a -12.93% decrease year-over-year.
MDxHealth SA ADR (MDXH) Cash Flow 2024
MDXH recorded a free cash flow (TTM) of -$30.56 million for the quarter ending September 30, 2023.
MDxHealth SA ADR (MDXH) Earnings per Share 2024
MDXH earnings per share (TTM) was -$2.00 for the quarter ending September 30, 2023, a +23.08% growth year-over-year.
About MDxHealth SA ADR
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
0.03%
Cap:
|
Volume (24h):